Introduction: When to Seek Diagnostic Testing

Liver cancer is a condition where the timing of diagnosis can significantly affect your options and outcomes. Unfortunately, many people with early liver cancer experience no symptoms at all, which is why it’s especially important to know when to seek testing. If you belong to a group at higher risk for liver cancer, regular screening becomes essential even before you feel unwell.^[1]

You should consider seeking diagnostic evaluation if you notice certain warning signs. These include a hard lump on the right side of your body just below your rib cage, discomfort in the upper right part of your abdomen, a swollen belly, pain near your right shoulder blade or in your back, or yellowing of your skin and the whites of your eyes (called jaundice). Other symptoms include easy bruising or bleeding, unusual tiredness that doesn’t go away, nausea and vomiting, loss of appetite or feeling full after eating very little, and unexplained weight loss.^[3]

It’s crucial to understand that many of these symptoms can be caused by conditions far less serious than liver cancer. However, if any of these signs last longer than two weeks, you should visit a healthcare provider. They can determine whether your symptoms require further investigation through diagnostic tests.^[4]

Certain groups of people face higher risk and should be particularly vigilant about diagnostic testing. If you have long-term hepatitis B or hepatitis C infection, you’re at increased risk for liver cancer. This is especially important because hepatitis often causes no symptoms, so many people don’t know they’re infected. The Centers for Disease Control and Prevention now recommends that every adult over age 18 get tested for both types of hepatitis at least once.^[7]

Other risk factors that should prompt you to discuss screening with your doctor include having cirrhosis from any cause, heavy alcohol use over many years, metabolic dysfunction-associated steatotic liver disease (a condition where excess fat builds up in your liver), obesity, Type 2 diabetes, smoking cigarettes, and certain inherited conditions affecting the liver. Most liver cancers develop in people who already have cirrhosis, with approximately 80% of cases occurring in this group.^[4]

Classic Diagnostic Methods for Identifying Liver Cancer

When doctors suspect liver cancer, they use several different approaches to confirm the diagnosis and understand the nature and extent of the disease. The diagnostic process typically begins with a physical examination and a detailed discussion about your symptoms and medical history. Your doctor will ask about risk factors like hepatitis infections, alcohol use, and any existing liver conditions.^[4]

Blood Tests

Blood tests play an important role in diagnosing liver cancer, though they cannot definitively prove cancer is present on their own. Your healthcare provider may check your liver function with blood tests that measure how well your liver is working. They may also test for a substance called alpha-fetoprotein, or AFP. This protein is produced by some liver cancers, and elevated levels in your blood can suggest the presence of cancer. However, not all liver cancers produce AFP, and some non-cancerous liver conditions can also raise AFP levels.^[4]

Other blood tests can check for hepatitis B and hepatitis C infections, which are major risk factors for liver cancer. These tests look for the viruses themselves or for antibodies that your body produces in response to infection.^[5]

Imaging Studies

Imaging tests create pictures of the inside of your body and are essential for detecting liver tumors. One important aspect of liver cancer diagnosis is that in many cases, especially for people with cirrhosis, cancer can be reliably diagnosed through imaging alone without needing a biopsy.^[9]

Ultrasound is often the first imaging test used. This painless test uses sound waves to create images of your liver. It can detect tumors and is frequently used for regular screening in people at high risk for liver cancer. For people with cirrhosis, ultrasound combined with an AFP blood test every six months is a common surveillance approach.^[4]

CT scans (computed tomography) use X-rays taken from different angles to create detailed cross-sectional images of your liver. A special type called a triple-phase CT scan is particularly useful for liver cancer. This test involves taking images during different phases of blood flow through your liver after contrast dye is injected. The pattern of how the tumor appears during these different phases can help doctors identify liver cancer.^[11]

MRI scans (magnetic resonance imaging) use powerful magnets and radio waves to create very clear, detailed images of the liver’s internal structure. Like CT scans, MRI can be performed with contrast material in phases to better characterize liver lesions. MRI is often excellent at distinguishing between different types of liver tumors.^[4]

For patients with cirrhosis and liver lesions larger than 1 centimeter, these triple-phase contrast-enhanced imaging studies can often diagnose liver cancer without requiring tissue sampling. The characteristic appearance of liver cancer on these scans is reliable enough that doctors can make treatment decisions based on imaging alone in many cases.^[11]

Specialized Imaging Tests

Sometimes additional imaging tests provide useful information. An angiogram examines the blood vessels in your liver by injecting contrast dye directly into the arteries. This can help doctors see the blood supply to a tumor, which is important for planning certain treatments.^[4]

For bile duct cancer within the liver, a test called ERCP (endoscopic retrograde cholangiopancreatography) may be performed. This involves passing a thin, flexible tube with a camera through your mouth, down through your stomach, and into the area where bile ducts enter the small intestine. Dye is injected to highlight the bile ducts on X-rays, helping doctors identify abnormalities.^[4]

Liver Biopsy

A biopsy involves removing a small sample of liver tissue to examine under a microscope. This is the most definitive way to diagnose cancer and determine its type. However, liver cancer is unique among cancers in that a biopsy is not always necessary. When imaging studies clearly show characteristic features of liver cancer in a person at high risk, doctors can often make the diagnosis without a biopsy.^[9]

When a biopsy is needed, it’s typically done using a thin needle inserted through the skin into the liver while ultrasound or CT imaging guides the needle to the right spot. The tissue sample is then sent to a laboratory where a specialist examines it to confirm whether cancer cells are present and what type they are.^[4]

Biopsies carry a small risk of complications, including bleeding, and there’s a theoretical concern that the needle could spread cancer cells along its path. For these reasons, doctors carefully consider whether a biopsy is truly necessary or whether imaging provides sufficient information.^[9]

Distinguishing Liver Cancer from Other Conditions

One crucial role of diagnostic testing is to differentiate primary liver cancer (cancer that starts in the liver) from secondary liver cancer (cancer that has spread to the liver from somewhere else in the body). This distinction is extremely important because treatment approaches differ dramatically. Cancers from the colon, breast, lung, or pancreas commonly spread to the liver. In fact, in people without underlying liver disease, metastatic cancer (cancer that has spread from another organ) is far more common than primary liver cancer.^[2]

Among primary liver tumors themselves, doctors must distinguish between different types. Hepatocellular carcinoma, which arises from liver cells called hepatocytes, is the most common type, accounting for over 75% of primary liver cancers. Cholangiocarcinoma, or bile duct cancer, accounts for about 8% to 20% of primary liver cancers and arises from the cells lining the bile ducts inside the liver. These two types behave differently and require different treatment approaches.^[2]

Doctors also need to distinguish cancer from benign (non-cancerous) liver growths. Common benign liver tumors include hemangiomas (clusters of blood vessels), hepatic adenomas, and focal nodular hyperplasia. These typically don’t require treatment unless they’re causing symptoms. The appearance on imaging studies helps doctors tell these apart from cancer.^[6]

Diagnostics Used for Clinical Trial Qualification

When researchers design clinical trials to test new treatments for liver cancer, they need to ensure that participants meet specific criteria. This standardization helps researchers understand whether a treatment works and makes results from different studies comparable. The diagnostic tests and criteria used for enrolling patients in clinical trials are often more detailed than those used in routine care.^[11]

Baseline Diagnostic Assessment

Before enrolling in a clinical trial, patients typically undergo comprehensive diagnostic testing to establish a baseline understanding of their cancer. This almost always includes detailed imaging studies, usually both CT and MRI scans, performed with contrast enhancement in multiple phases. These scans document the size, number, and location of tumors, providing a starting point against which treatment effects can be measured.^[11]

Blood tests are also standard for trial enrollment. In addition to checking liver function and blood cell counts, trials often require measurement of alpha-fetoprotein levels. Some trials specifically enroll patients based on whether their AFP is elevated or normal, as this can affect how the cancer behaves and responds to treatment.^[11]

Confirmation of Diagnosis and Cancer Type

While imaging alone may be sufficient for clinical care, many clinical trials require tissue confirmation through biopsy. Researchers want to be absolutely certain about the diagnosis and may need tissue samples to test for specific molecular markers or genetic characteristics that could predict response to experimental treatments. The biopsy tissue may be examined not just to confirm cancer but also to analyze specific proteins or genes that the new treatment targets.^[11]

Staging and Performance Status

Clinical trials typically enroll patients at specific stages of disease. Staging systems for liver cancer take into account the size and number of tumors, whether cancer has spread beyond the liver, how well the liver is functioning, and the patient’s overall physical condition. Common staging systems include the Barcelona Clinic Liver Cancer (BCLC) system, which divides patients into stages labeled 0, A, B, C, and D based on these factors.^[11]

Trials also assess what’s called performance status, which is a measure of how well you can carry out normal daily activities. This helps ensure that patients are well enough to tolerate the experimental treatment and that researchers can properly evaluate its effects versus effects of declining overall health.^[11]

Liver Function Assessment

Because most liver cancer patients have underlying liver disease, assessing how well the liver is working is critical for trial enrollment. Tests measure levels of substances like bilirubin (which causes jaundice when elevated), albumin (a protein made by the liver), and clotting factors that the liver produces. These are often combined into scoring systems like the Child-Pugh score, which classifies liver function as Class A (best), B (intermediate), or C (worst).^[11]

Many trials only accept patients with Child-Pugh Class A or early Class B liver function because patients with worse liver function may not tolerate treatment well, making it difficult to determine whether problems are due to the treatment or the underlying liver disease.^[11]

Molecular and Genetic Testing

As treatments for liver cancer become more targeted and personalized, clinical trials increasingly require testing of tumor tissue or blood for specific molecular markers. For example, some trials test for mutations in genes like TP53, CTNNB1, or TERT, or for proteins that indicate how the immune system is interacting with the tumor. These tests help match patients to treatments most likely to benefit them.^[5]

Exclusion Criteria Testing

Trials also perform tests to ensure patients don’t have conditions that would make participation unsafe or that would interfere with evaluating the treatment. This might include tests to confirm that cancer hasn’t spread to the brain, that kidney function is adequate, or that heart function is normal. Testing for active infections, including hepatitis status and HIV status in some cases, is also standard.^[11]